company:pfizer
Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
company:pfizer
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
drug:danuglipron
Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?